Advertisement

Topics

Top five promising drugs Phase III (February 2014)

03:38 EDT 23rd September 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS February 2014

Drug Disease Company
Lu-AE58054 Alzheimer’s disease H. Lundbeck / Otsuka Pharmaceutical
Patisiran Transthyretin-mediated amyloidosis Alnylam Pharmaceuticals
Duvelisib Chronic lymphocytic leukemia / Small lymphocytic lymphoma Infinity Pharmaceuticals
Selumetinib Non-small-cell lung cancer AstraZeneca
Ertugliflozin Type 2 diabetes Pfizer / Merck & Co

 

 

 

 

 

 

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

Quick Search
Advertisement
 

review and buy Top five promising drugs Phase III (February 2014) market research data and corporate reports here